Krka d. d Market Cap ($9.28 Billion)
Market Cap & Net Worth: Krka d. d (KRK)
Krka d. d market cap. Krka d. d (WAR:KRK) has a market capitalization of $9.28 Billion (zł33.73 Billion) as of October 30, 2026. Listed on the WAR stock exchange, this Poland-based company holds position #2308 globally and #14 in its home market, demonstrating a -0.71% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Krka d. d's stock price zł1114.00 by its total outstanding shares 30276867 (30.28 Million).
Krka d. d Market Cap History (2015–2026)
Krka d. d market cap history from 2015 to 2026. Data shows growth from $1.48 Billion to $9.28 Billion (18.65% CAGR). Check KRK stock price and chart for real-time trading data and today's change.
Krka d. d Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Krka d. d's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see cash flow conversion of Krka d. d for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
3.51x
Krka d. d's market cap is 3.51 times its annual revenue
Latest Price to Earnings (P/E) Ratio
17.76x
Krka d. d's market cap is 17.76 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.37 Billion | $1.17 Billion | $108.45 Million | 1.16x | 12.60x |
| 2017 | $1.35 Billion | $1.27 Billion | $152.60 Million | 1.07x | 8.87x |
| 2018 | $1.50 Billion | $1.33 Billion | $174.59 Million | 1.13x | 8.60x |
| 2019 | $1.98 Billion | $1.49 Billion | $245.54 Million | 1.32x | 8.05x |
| 2020 | $2.89 Billion | $1.53 Billion | $291.00 Million | 1.88x | 9.94x |
| 2021 | $3.88 Billion | $1.57 Billion | $309.21 Million | 2.48x | 12.56x |
| 2022 | $3.25 Billion | $1.72 Billion | $363.30 Million | 1.90x | 8.96x |
| 2023 | $3.83 Billion | $1.81 Billion | $313.95 Million | 2.12x | 12.19x |
| 2024 | $4.88 Billion | $1.91 Billion | $356.99 Million | 2.56x | 13.68x |
| 2025 | $7.17 Billion | $2.04 Billion | $403.43 Million | 3.51x | 17.76x |
Competitor Companies of KRK by Market Capitalization
Companies near Krka d. d in the global market cap rankings as of October 30, 2026. See KRK equity to assets ratio to understand what proportion of total assets are financed by equity.
Key companies related to Krka d. d by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #600 globally with a market cap of $45.38 Billion USD ( CN¥310.15 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #626 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.98 |
| #600 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.38 Billion | CN¥48.62 |
| #626 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €17.90 |
Market Capitalization of Krka d. d (2015–2026)
Market capitalization of Krka d. d from 2015 to today. Between 2015 and today, Krka d. d's market cap moved from $1.48 Billion to $ 9.28 Billion, with a yearly change of 18.65%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | zł9.28 Billion | +29.53% |
| 2025 | zł7.17 Billion | +46.76% |
| 2024 | zł4.88 Billion | +27.63% |
| 2023 | zł3.83 Billion | +17.54% |
| 2022 | zł3.25 Billion | -16.20% |
| 2021 | zł3.88 Billion | +34.28% |
| 2020 | zł2.89 Billion | +46.35% |
| 2019 | zł1.98 Billion | +31.68% |
| 2018 | zł1.50 Billion | +10.85% |
| 2017 | zł1.35 Billion | -0.94% |
| 2016 | zł1.37 Billion | -7.96% |
| 2015 | zł1.48 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Krka d. d was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.28 Billion USD |
| MoneyControl | $9.28 Billion USD |
| MarketWatch | $9.28 Billion USD |
| marketcap.company | $9.28 Billion USD |
| Reuters | $9.28 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Krka d. d
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, an… Read more